Top 5 Drug Type | Count |
---|---|
Monoclonal antibody | 7 |
Biological products | 2 |
Antibody drug conjugate (ADC) | 2 |
Live biotherapeutic products | 2 |
Antibody | 1 |
Target |
Mechanism PDL1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date23 Mar 2017 |
Target- |
Mechanism Bacteria replacements [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Bacteria replacements [+1] |
Active Org. |
Originator Org. ![]() |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Feb 2024 |
Sponsor / Collaborator |
Start Date18 Sep 2023 |
Sponsor / Collaborator [+1] |
Start Date16 Mar 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
GEN-001 | Biliary Tract Neoplasms More | Phase 2 |
Avelumab ( PDL1 ) | Advanced Malignant Solid Neoplasm More | Phase 1 |
GENA-104A16 ( CNTN4 ) | Advanced Malignant Solid Neoplasm More | Phase 1 |
SB-121 | Autistic Disorder More | Phase 1 |
GENA-004 | Infertility More | Early Phase 1 |